Pfizer Ltd. posts Q1 FY25 PAT at Rs. 150.71 Cr

Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024

Akums breaks ground for its first overseas manufacturing facility in Zambia

It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products

Zydus receives approval from Health Canada for Mesalamine suppositories

Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis

Syngene International expands capabilities with new bioconjugation suite in Bengaluru

Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services

Glenmark Pharmaceuticals USA to launch Ropivacaine Hydrochloride Injection USP

Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA

Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV

Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients

Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients

Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile

Bajaj Healthcare posts Q2 FY26 PAT at Rs. 11.10 Cr

Bajaj Healthcare has reported total income of Rs. 149.56 crore during the period ended September 30, 2025

Biocon Biologics and Civica launch private-label Insulin glargine

Supriya Lifescience honoured for outstanding export excellence by Govt. of Maharashtra